[A controlled study on the action of a new formulation of ambroxol in asthmatiform bronchitis in children].
A comparison between the action of Ambroxol and Acetylcysteine was carried out in 28 children aged 2 to 13 (mean 7 years 3 months) affected with spastic bronchitis. 14 patients were treated daily for 10 days by the oral route with 30 mg of Ambroxol (2 sachets) and 14 with 200-300 mg of Acetylcysteine (2-3 sachets). Quantity and quality of sputum, difficulty in expectorating, cough, dyspnea, bronchial bruits, were assessed before the treatment, 5 days into it and at the end. Both drugs were effective and well tolerated, but Ambroxol proved to be more rapid in achieving a satisfactory improvement than Acetylcysteine.
Baldini
G
G
Gucci
M
M
Tarò
D
D
Memmini
C
C
D000111:Acetylcysteine / Q000008:administration & dosage / Q000627:therapeutic use; D000293:Adolescent; D000551:Ambroxol / Q000008:administration & dosage / Q000627:therapeutic use*; D001964:Bromhexine / Q000031:analogs & derivatives*; D001991:Bronchitis / Q000188:drug therapy*; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D008173:Lung Diseases, Obstructive / Q000188:drug therapy*; D008297:Male; D011897:Random Allocation; D013997:Time Factors
D000551:Ambroxol; D001964:Bromhexine; D000111:Acetylcysteine
Studio clinico controllato sull'attività di una nuova formulazione di ambroxol nella bronchite asmatiforme del bambino.